Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Steven Keith Burke Sells 50,506 Shares

Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Steven Keith Burke sold 50,506 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $106,062.60. Following the completion of the sale, the senior vice president now owns 816,234 shares in the company, valued at approximately $1,714,091.40. The trade was a 5.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Akebia Therapeutics Price Performance

Shares of AKBA stock opened at $2.14 on Wednesday. The stock has a market cap of $466.91 million, a P/E ratio of -9.30 and a beta of 0.74. Akebia Therapeutics, Inc. has a one year low of $0.80 and a one year high of $2.48. The stock has a fifty day moving average price of $2.00 and a 200 day moving average price of $1.67.

Akebia Therapeutics (NASDAQ:AKBA) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The company had revenue of $37.43 million during the quarter, compared to analysts’ expectations of $45.66 million. During the same period in the prior year, the business posted ($0.08) earnings per share. Equities research analysts anticipate that Akebia Therapeutics, Inc. will post -0.3 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $7.50 price objective on shares of Akebia Therapeutics in a research note on Thursday, January 23rd. StockNews.com cut Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AKBA. Empirical Asset Management LLC bought a new position in shares of Akebia Therapeutics during the third quarter valued at $44,000. B. Riley Wealth Advisors Inc. bought a new position in shares of Akebia Therapeutics during the second quarter valued at $44,000. XTX Topco Ltd bought a new position in shares of Akebia Therapeutics during the third quarter valued at $58,000. Intech Investment Management LLC bought a new position in shares of Akebia Therapeutics during the third quarter valued at $59,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Akebia Therapeutics by 205.8% during the third quarter. BNP Paribas Financial Markets now owns 46,270 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 31,137 shares during the period. 33.92% of the stock is owned by institutional investors.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.